PTO/SB/08a (08-03)
Approved for use through 97/31/2006, OMS 0651-0201
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE to a collection of information unfers it contains a valid OMS control number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10599237				
Filing Date		2006-09-22				
First Named Inventor	Kohe	NAKATA				
Art Unit		TBA				
Examiner Name	TBA					
Attorney Docket Number		49288.3700				

					U.S.	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number Kind Code! Issue Date Name of Patentee or Applicar of cited Document			Releva	,Columns,Lines whe ant Passages or Rele s Appear				
	1									
If you wis	h to a	i dd additional U.S. Pate	nt citatio	n inform	ation pl	l lease click the	Add button.		Add	
-			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant of cited Document		Releva	Columns,Lines whe ant Passages or Rele s Appear	
	1									
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d button	Add	
				FOREIG	SN PA1	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Line where Relevant Passages or Releva Figures Appear	TE
	1	10-107623	JP			1998-04-24	Sony Corp			
	2	09-023157	JP			1997-01-21	Pioneer Electron C	огр		
	3	10/031869	JP			1998-02-03	Pioneer Electron C	orp		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10599237		
iling Date		2006-09-22		
irst Named Inventor	Kohei NAKATA			
Art Unit		TBA		
xaminer Name	TBA			
Manager Dealest Number		40399 3700		

	4	2004-	095151	JP		2004-03-25	Victor Co of Japan Ltd		
If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
NON-PATENT LITERATURE DOCUMENTS Remove									
Examiner Cite Initials* Cite Cook, and the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item initials* Cite (book, magazine, journat, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								Τs	
	1								
If you wish to add additional non-patent literature document citation information please click the Add button Add									
EXAMINER SIGNATURE									
Examiner Signature Date Considered									
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant									

See for Codes of USPTO Platent Documents at year, LIBETO,000 or MPEP 001.04. Feater office and issued for document, by the ho-letter code (WIPO Standard STI), 3. Feater office and the importance part of the depth of the import many proceed the set of in under the papert of the region of the import many proceed the set of in under the papert of the paper of the region of the importance paper of the septomate of the papert of the paper of the paper of the region of the importance paper of the pap

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10599237		
	Filing Date		2006-09-22		
	First Named Inventor	Kohei	NAKATA		
	Art Unit		тва		
	Examiner Name TBA Attorney Docket Number				
			49288 3700		

CERTIFICATION STATEMENT

Diagon con	37	CFR .	1 97	and	1 02	n make	the	annonniata	selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign parter office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 159(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1379(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Howard I Sobelman

□ None

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

ionii oi tre signature.			
Signature	/Howard I Sobelman/	Date (YYYY-MM-DD)	2006-11-09

Registration Number

39038

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiling. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.